Protagonist Therapeutics/PTGX

$31.71

1.43%
-
1D1W1MYTD1YMAX

About Protagonist Therapeutics

Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).

Ticker

PTGX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Dinesh Patel

Employees

124

Headquarters

Newark, United States

PTGX Metrics

BasicAdvanced
$1.8B
Market cap
12.71
P/E ratio
$2.46
EPS
2.14
Beta
-
Dividend rate
$1.8B
2.14087
$33.34
$13.72
564K
15.724
9.313
37.3%
41.75%
40.23%
12.712
5.821
3.269
3.271
36,565.07%
186.78%
27.97%

What the Analysts think about PTGX

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
41.28% upside
High $52.00
Low $38.00
$31.71
Current price
$44.80
Average price target

PTGX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
81.32% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$255M
324.83%
Net income
$207M
659.34%
Profit margin
81.32%
78.73%

PTGX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 173.08%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.68
-$0.58
$0.44
$3.26
-
Expected
-$0.65
-$0.69
-$0.03
$1.19
-$0.60
Surprise
5.05%
-16.41%
-1,425.3%
173.08%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Protagonist Therapeutics stock?

Protagonist Therapeutics (PTGX) has a market cap of $1.8B as of May 22, 2024.

What is the P/E ratio for Protagonist Therapeutics stock?

The price to earnings (P/E) ratio for Protagonist Therapeutics (PTGX) stock is 12.71 as of May 22, 2024.

Does Protagonist Therapeutics stock pay dividends?

No, Protagonist Therapeutics (PTGX) stock does not pay dividends to its shareholders as of May 22, 2024.

When is the next Protagonist Therapeutics dividend payment date?

Protagonist Therapeutics (PTGX) stock does not pay dividends to its shareholders.

What is the beta indicator for Protagonist Therapeutics?

Protagonist Therapeutics (PTGX) has a beta rating of 2.14. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Protagonist Therapeutics stock price target?

The target price for Protagonist Therapeutics (PTGX) stock is $44.8, which is 41.28% above the current price of $31.71. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Protagonist Therapeutics stock

Buy or sell Protagonist Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing